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Abstract
Aims/hypothesis Islet autoimmunity usually starts with the appearance of autoantibodies against either insulin (IAA) or GAD65
(GADA). This categorises children with preclinical type 1 diabetes into two immune phenotypes, which differ in their genetic
background and may have different aetiology. The aim was to study whether Coxsackievirus group B (CVB) infections, which
have been linked to the initiation of islet autoimmunity, are associated with either of these two phenotypes in children with HLA-
conferred susceptibility to type 1 diabetes.
Methods All samples were from children in the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study. Individuals are
recruited to the DIPP study from the general population of new-born infants who carry defined HLA genotypes associated with
susceptibility to type 1 diabetes. Our study cohort included 91 children who developed IAA and 78 children who developed
GADA as their first appearing single autoantibody and remained persistently seropositive for islet autoantibodies, along with 181
and 151 individually matched autoantibody negative control children, respectively. Seroconversion to positivity for neutralising
antibodies was detected as the surrogate marker of CVB infections in serial follow-up serum samples collected before and at the
appearance of islet autoantibodies in each individual.
Results CVB1 infections were associated with the appearance of IAA as the first autoantibody (OR 2.4 [95% CI 1.4, 4.2],
corrected p = 0.018). CVB5 infection also tended to be associated with the appearance of IAA, however, this did not reach
statistical significance (OR 2.3, [0.7, 7.5], p = 0.163); no other CVB types were associated with increased risk of IAA. Children
who had signs of a CVB1 infection either alone or prior to infections by other CVBs were at the highest risk for developing IAA
(OR 5.3 [95% CI 2.4, 11.7], p < 0.001). None of the CVBs were associated with the appearance of GADA.
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Introduction
Recent studies have suggested that the pathogenesis of
type 1 diabetes is heterogeneous. One of the most impor-
tant indicators of this heterogeneity is seen during the
early phases of islet autoimmunity and is characterised
by the specificity of the first appearing autoantibody
targeting either insulin or the 65 kD isoform of glutamic
acid decarboxylase (GAD), known as IAA and GADA,
respectively. Both insulin and GAD are present in beta
cells together with insulin secretary granules [1]. Insulin
constitutes 50% of the total protein content of the beta
cells and plays a major role as an autoantigen in type 1
diabetes [2]. It is almost exclusively expressed in beta
cells, although small amounts can also be found in some
neuronal cells and in the thymus [3]. The expression of
GAD on the other hand, is not limited to beta cells but
can be seen in all islet cells including alpha and delta cells
as well as in the nervous system and to a lesser extent in
the lungs [4]. The IAA driven autoimmune process typi-
cally starts at a younger age than the GADA-driven pro-
cess [5] and these two phenotypes of type 1 diabetes dif-
fer from each other in their genetic background since the
IAA phenotype associates with the HLA-DR4-DQ8 hap-
lotype and INS gene polymorphism, whereas the GADA
phenotype is primarily associated with the HLA-DR3-
DQ2 haplotype [6].
It is possible that each of these phenotypes has a different
aetiology and relate to different beta cell damaging processes.
The aim of the present study was to investigate whether strains
of Coxsackievirus group B (CVB); one of the strongest
•
•
•
•
•
•
•
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environmental triggering candidates for type 1 diabetes [7, 8],
are associated with the initiation of islet autoimmunity in ei-
ther of these two phenotypes.
Methods
Study cohort The Type 1 Diabetes Prediction and Prevention
(DIPP) study is a population-based observational study that
was launched in Finland in 1994. The study has been ap-
proved by the ethical committees of the hospital districts of
Southwest Finland (Turku University Hospital), Pirkanmaa
(Tampere University Hospital) and Northern Ostrobothnia
(Oulu University Hospital) and the parents of the participating
children gave their informed written consent to the participa-
tion in the study. Formal assent was not sought from children,
as this was not required under Finnish law and ethical regula-
tions. However, children were informed about the procedure
at a level appropriate for their age and understanding. In this
study cord blood samples from all individuals with parental
consent are analysed for the presence of HLA-DR/DQ alleles
and children with genotypes associated with increased risk for
type 1 diabetes are recruited for follow-up [9]. HLA screening
criteria were modified during the DIPP study to identify a
larger repertoire of DQB1 and DQA1 alleles, along with
HLA-DRB1*04 subtypes which increased the sensitivity
and specificity of the risk estimation for type 1 diabetes [5,
10]. Blood samples were collected regularly at 3–12 month
intervals and islet cell antibodies (ICA), IAA, GADA and islet
antigen 2 autoantibody 2 (IA-2A) have been analysed [11].
Prior to 2003, ICA was used as a primary screening marker
meaning that if the child turned ICA positive then biochemical
autoantibodies (IAA, GADA and IA-2A) were analysed from
all available samples from that child.
Study design All individuals (N = 169) were selected among
those who became seropositive for a single autoantibody (IAA
[n = 91] or GADA [n = 78]) but seroconverted persistently to
any combinations of additional autoantibodies (multiple islet
autoantibodies) during the follow-up period. We used all
available individuals in the study from whom the serum sam-
ple sets were available. The mean (±SD) age of the ‘case’
children in the ‘IAA first’ group was 21.4 ± 14.9 months com-
pared with 58.2 ± 34.4 months in children in the ‘GADA first’
group, p < 0.001. Altogether 31.9% of case children in the
IAA first group and 39.7% of case children in the GADA first
group were girls (p = 0.37). Five (5.5%)mothers of children in
the IAA first group and two (2.6%) mothers of children in the
GADA first group had type 1 diabetes at the time of the child’s
birth. By February 2016, 66 children in the IAA first group
(72.5%) and 29 in the GADA first group (37.2%) had
progressed to type 1 diabetes (diagnosed according to WHO
criteria [12]). Two autoantibody negative ‘control’ children
werematched to each case child individually according to date
of birth (±1 month), sampling date (±2 months), sex, regis-
tered study centre and HLA-DQB1 risk alleles to form control
groups. In total, there were 181 control children for the IAA
first group and 151 control children for the GADA first group.
On a few occasions only one control child for a case child met
the inclusion criteria. The age at first introduction of dairy
products in the child’s diet did not differ between case and
control children in either of these groups (data not shown).
Virus antibody measurement A standard plaque reduction as-
say was used to identify neutralising effect of antisera. Briefly,
fourfold dilutions of sera in volumes of 3 μl were incubated
with equal volume of approximately 100 PFU infectious virus
for 1 h at 37°C, continued overnight at room temperature. The
volume of each reaction was made up to 100 μl using Hanks’
Balanced Salt solution (HBSS)-HEPES. Suspensions were
incubated with 95% confluent GMK cells maintained in min-
imum essential medium (MEM; Sigma) in 12 well plates
(Nunc) for 1 h at 37°C. Cells were then covered with semi-
solid media (MEM supplemented with 0.67% carboxymethyl
cellulose) after removing the virus–serum suspension and in-
cubated for 2 days at 37°C in a humid chamber supplemented
with 5% CO2. Virus plaques were visualised and quantified
after fixing the cells with formaldehyde solution containing
crystal violet. A reduction in plaque number ≥80% compared
with untreated virus suspension was considered positive.
Study samples, shown in Fig. 1, included cord blood serum
at birth and further blood samples at the autoantibody sero-
conversion time, 6 months prior to the autoantibody serocon-
version (−6 M) and 12 months prior to the autoantibody sero-
conversion (−12 M). Neutralising antibodies against all six
members of the CVB group (CVB1-6) were analysed using
a sensitive plaque reduction assay with blinding to the
case/control status of the child. Persistent seroconversion to
CVB neutralising antibody positive in consecutive samples
was used as the criterion to identify virus infections. To enable
this, an algorithm was developed which is shown in ESM
Fig.1. The algorithm was first validated by comparing the
results to those from two experts with identical diagnostic
criteria and was subsequently used to identify the CVB infec-
tions. The algorithm also took into account the possible pres-
ence of maternal CVB antibodies and was used to eliminate
any possible biasing effect of such maternal antibodies on the
diagnosis of the child’s infections. The increased serum titers
for virus-specific antibodies were identified to diagnose virus
infections using this algorithm.
Statistical analysis The conditional logistic regression meth-
od was employed since triplets (the case and two control
children) were matched for age, sex, HLA and birth region
using the R statistical package (version 3.2.2, www.r-project.
org) to generate OR and 95% CIs with Wald’s statistics
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(representing unadjusted two-sided p values). Bonferroni ad-
justment for the p value was used where appropriate in the
statistical analysis.
The aim was to identify the association of infections by
CVBmembers individually to the risk of developing subtypes
of autoimmunity to islet autoantigens (IAA or GADA).
Therefore, the proportion of case children who had CVB in-
fections at any time point before autoantibody seroconversion
were compared with the proportion of their matched control
children who had CVB infection by the corresponding age (as
pre-specified, each CVB serotype was analysed separately).
Both crude p values and the p values corrected for the number
of comparisons (Bonferroni correction) are presented for this
primary analysis (Table 1).
The temporal profile of the associations was also
established in time-window analyses (time windows are
shown in Fig. 1). For this, timing of the CVB infections that
occurred before the detection of predictive autoantibodies was
analysed using the same statistical method as described above
for IAA and GADA first groups separately.
The impact of the order of infections caused by different
CVB serotypes on the risk of beta cell autoimmunity was also
analysed using data from longitudinal sample sets by condi-
tional logistic regression.
Interactions between different serotypes in exposing the
children to islet autoimmunity (IAA or GADA) were also
analysed using the same statistical method by studying the
effect of different virus combinations.
The overall number of samples from the different time
points did not differ between case and control children (aver-
age 3.6 samples per case and 3.5 samples per control child in
both the IAA and in the GADA group) and conditional logis-
tic regression analyses (by definition) were carried out using
the data from only those samples that were available from the
same time point from both the case and control children.
Results
CVB infections and initiation of insulin-driven islet autoimmu-
nity CVB1 infections were associated with insulin-driven au-
toimmunity (IAA). The odds of being infected before the first
detection of IAA was higher in case children compared with
the individually matched control children (OR 2.4 [95% CI
1.4, 4.2], corrected p = 0.02; Table 1). This association was
also detected when clinical type 1 diabetes was used as the
endpoint event (OR 3.1 [95% CI 1.6, 6.2], corrected p =
0.006; ESM Table 1). Other CVB types were not associated
with increased risk of IAA or type 1 diabetes. CVB5 also
tended to have a risk association with IAA autoimmunity,
however, this did not reach statistical significance (OR 2.3
[95% CI 0.7, 7.5], p = 0.2; Table 1).
CVB infections and initiation of GAD-driven islet autoimmu-
nity In contrast to insulin-driven autoimmunity, the risk of
GAD-driven autoimmunity was not associated with CVB1 or
other CVB infections (Table 1). Since children in the GADA
first group were older than those in the IAA first group, to
eliminate the possibility of increasing CVB infection due to
age masking the effect of earlier infections on GADA autoim-
munity we performed similar analyses by restricting the age of
seroconversion to 2 years (ESM Table 2). CVB1 infection was
not associated with GADA in these young children (OR 0.8
[95% CI 0.2, 2.9], p = 0.751) while it was still associated with
an increased risk of IAA autoimmunity in this age group
(OR 2.3 [95% CI 1.2, 4.3], p = 0.01). This was also true for
CVB1 infections among children who developed type 1
diabetes (OR 2.7 [95% CI 1.3, 5.5], p = 0.01; IAA first group).
Timing of CVB1 infections The potential association between
CVB1 infections and the initiation of islet autoimmunity was
studied further by analysing the timing of infections in relation
to the first detection of islet autoantibodies, using previously
defined time windows (shown in Fig. 1): autoantibody posi-
tive (AAb+) window including a 6 month period prior to the
time of autoantibody seroconversion, a 6 month period before
autoantibody window (−6 M window) and the period prior to
the −6 month window (−12 M window). In the IAA first
group, the risk was associated with CVB1 infections that oc-
curredwithin a year before the first detection of IAA (Table 2).
This included both the autoantibody positive and −6 M win-
dows (OR 2.3 [95%CI 1.1, 4.5], p = 0.02 and OR 2.9 [95%CI
1.3, 6.7], p = 0.01, respectively; Table 2). In the GADA first
group, however, CVB1 infections were not associated with
Cord blood serum at birth                                              −12 month sample         −6 month sample           AAb time sample                           Type 1 diabetes 
−12 months’ window           −6 months’ window            AAb
+
 window 
Autoimmunity timeline (months) -18 -17 -16 -15 -14 -13 -12 -11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0
Fig. 1 Schematic representation of the sampling time and the time win-
dows used in the statistical analysis. Serum samples taken for the analysis
included the first follow-up serum that was positive for islet autoanti-
bodies (AAb time) as well as samples taken 6 and 12 months prior to
the first autoantibody positive sample and the cord blood sample. The
time window between AAb time and −6 month sample was called the
AAb+ window, indicating the autoantibody seroconversion occurred in
this time window. The time window between −6 month sample and
−12 month sample was called −6 months’ window and the time window
before −12 month sample was called −12 months’ window. AAb,
autoantibody
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the risk of islet autoimmunity in any of these time windows
(Table 2). The time-associations in the IAA first group with
the autoantibody positive window was also seen in those chil-
dren who progressed to clinical type 1 diabetes (OR 1.6 [95%
CI 1.1, 2.5], p = 0.025).
Modifying the risk association of CVB1 infection with insulin-
driven autoimmunity by other CVB infections Since past in-
fections by different CVBs can influence the course of later
CVB1 infection e.g. by providing some immunological cross-
protection we wanted to study whether a prior history of CVB
infections modulates the association between CVB1 and
insulin-driven autoimmunity. For this purpose, we classified
CVB into two groups: (1) CVB types that showed increased
odds for IAA seroconversion and (2) CVB types that were not
associated with IAA or showed decreased odds. Based on the
data shown in Table 1, CVB1 and CVB5 were included in the
first category and the other four CVBs were placed in the
second category. Being infected by either CVB1 or CVB5 or
both (CVB1/5), was associated with increased risk of insulin-
driven autoimmunity (OR 2.7 [95% CI 1.4, 5.3], p = 0.003;
ESM Table 2). In contrast, being infected by any combination
of the other CVBs (CVB2/3/4/6) was associated with reduced
risk of insulin-driven autoimmunity (OR 0.4 [95% CI 0.2,
0.8], p = 0.007; ESM Table 2). Combining CVB1–6 infec-
tions into one group did not show any association with
insulin-driven autoimmunity. CVB1/5 infection was also as-
sociated with increased risk of islet autoimmunity and type 1
Table 1 Association between
CVB infections and two pheno-
types of progressive islet autoim-
munity (IAA first or GADA first)
Category Virus Infections (%) OR (95% CI) p value aCorrected p value
Controls Cases
IAA firstb CVB1 45.6 64.8 2.4 (1.4, 4.2) 0.003 0.018
CVB2 61.1 48.4 0.6 (0.3, 1.0) 0.031 0.186
CVB3 16.1 6.6 0.4 (0.2, 0.9) 0.034 0.204
CVB4 12.8 7.7 0.5 (0.2, 1.4) 0.181
CVB5 3.9 7.7 2.3 (0.7, 7.5) 0.163
CVB6 28.9 23.1 0.7 (0.4, 1.2) 0.204
GADA firstc CVB1 50.3 52.6 1.1 (0.6, 1.8) 0.850
CVB2 51 51.3 1.0 (0.6, 1.8) 0.923
CVB3 11.3 7.7 0.5 (0.2, 1.7) 0.295
CVB4 11.9 9 0.7 (0.3, 2.0) 0.507
CVB5 15.2 10.3 0.7 (0.3, 1.6) 0.335
CVB6 37.7 30.8 0.7 (0.4, 1.3) 0.277
Proportion of infected individuals are presented among case and control children prior to the autoimmunity
process
OR was calculated using conditional logistic regression with the control children being the reference group
a Bonferroni correction for six comparisons was used to generate corrected p values
b n = 181 for control children and 91 for case children
c n = 151 for control children and 78 for case children
The missing corrected p values were not significant and are, hence, not included
Table 2 Time-window analysis for CVB1
Phenotype Time window Infection % OR (95% CI) p value
Control Case
IAA firsta Neg. 54.1 35.2 Ref.
AAb+ 21.5 29.7 2.3 (1.1, 4.5) 0.019
−6 months 10.5 18.7 2.9 (1.3, 6.7) 0.010
−12 months 13.8 16.5 2.0 (0.8, 4.8) 0.122
GADA
firstb
Neg. 49.7 47.4 Ref.
AAb+ 19.2 17.9 0.9 (0.4, 1.9) 0.797
−6 months 7.3 5.1 0.5 (0.1, 2.3) 0.374
−12 months 23.8 29.5 1.3 (0.4, 1.9) 0.436
A schematic presentation of the framework for time-dependent analyses
Time-dependent risk association of beta cell autoimmunity with CVB1
infection in IAA first or GADA first groups (different autoimmune phe-
notypes) is shown here
Children who had no CVB1 infection at any time window were used as
the reference group (‘Neg.’ in the table)
The proportion of children who experienced CVB1 infection ‘for the first
time’ at any time within the time windows prior to islet autoimmunity has
been identified among case and control children
The analysis was performed for each autoimmune phenotype separately
a n = 181 for control children and 91 for case children
b n = 151 for control children and 78 for case children
Ref, Reference group; AAb, autoantibody
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diabetes in the IAA first but not in the GADA first group
(ESM Table 2).
To study the risk modification by CVB infections children
were further grouped into four categories based on their infec-
tion history including: (1) CVB1/5− and CVB2/3/4/6+; (2)
CVB1/5− and CVB2/3/4/6−, (3) CVB1/5+ and CVB2/3/4/6−
and (4) CVB1/5+ and CVB2/3/4/6+ (Table 3). The risk of
insulin-driven autoimmunity was the highest in children who
had CVB1/5 infections without any CVB2/3/4/6 infection
(OR 10.5 [95% CI 3.7, 29.8], p < 0.001). IAA autoimmunity
was also associated with CVB1/5 infections occurring with
other CVB infections (OR 3.7 [95% CI 1.5, 7.2], p = 0.002),
however, the odds were lower compared with the presence of
only CVB1/5 infection. Similar results were obtained when
CVB1 alone was included in the first group instead of both
CVB1 and CVB5 (ESM Table 3).
To assess the effect of the chronological order of these
infections, the children were grouped into four categories:
(1) Children who had experienced CVB2/3/4/6 alone or pri-
or to CVB1/5 (the reference group); (2) children who had no
CVB infection at all; (3) children infected with any combi-
nations of CVB1/5 alone or before CVB2/3/4/6 and (4)
when simultaneously infected with CVB1/5 and any combi-
nations of CVB2/3/4/6 (Table 4). The children who experi-
enced CVB1/5 infection alone or before any CVB2/3/4/6
had clearly the highest risk of insulin-driven autoimmunity
(OR 5.3 [95% CI 2.4, 11.7], p < 0.001; Table 4).
Simultaneous infections by CVB1/5 and CVB2/3/4/6 also
increased the risk (OR 2.6 [95% CI 1.3, 5.2], p = 0.007).
Similar results were obtained when CVB1 alone, without
CVB5, was included in the analysis (ESM Table 4). When
the timing of CVB1 and CVB5 infections was analysed in
relation to the time of first detection of islet autoantibodies
the risk association was related to CVB1/CVB5 infections
that occurred within 1 year prior to IAA seroconversion
(ESM Table 5).
Discussion
The present study shows that CVB infections may contribute
to the initiation of islet autoimmunity characterised by IAA as
the first appearing autoantibody. This particular group of chil-
dren are known as one of the phenotypes of islet autoimmu-
nity in man [6]. This recently discovered phenotype of type 1
diabetes differs from the other typical disease phenotype
characterised by initiation of autoimmunity against GAD [5,
6]. The fact that the initiation of islet autoimmunity in these
two phenotypes is associated with distinct HLA-DQ alleles
indicates that they might have different triggers for the disease
process leading to overt type 1 diabetes and different patho-
genetic mechanisms [5, 6]. Our study suggests that specific
CVB infections may contribute to the activation of the ‘insu-
lin-driven’ pathogenetic pathway. This finding motivates fur-
ther exploration of the pathogenic mechanisms underlying
human type 1 diabetes related to CVB infections.
The current study supports the previous observations that
enterovirus infections (including CVB) may increase the risk
of islet autoimmunity and type 1 diabetes [7, 8]. In addition,
the results imply that certain CVB infections might trigger the
insulin-driven autoimmune process. The observation that no
risk associations were seen between CVB infections and the
GADA-driven pathway and that the association appears to be
specific to CVB1 argues against the effect of unknown con-
founding factors. Additionally, to minimise any sampling bias
and the effect of possible confounders, case and control chil-
dren were individually matched for HLA-DQB1 genes, sex,
age, sampling dates and the region of birth. The findings from
the present study are also in line with those recently published
by The Environmental Determinants of Diabetes in the Young
(TEDDY) study [13]. In the TEDDY study parent-reported
recent respiratory infections, particularly common cold,
influenza-like illness, sinusitis and laryngitis/tracheitis were
associated with the subsequent risk of islet autoimmunity.
Table 3 Risk of insulin-driven
islet autoimmunity (IAA first)
according to the history of a
CVB1/5 infection vs other CVB
infections
Virus positivity Infection % OR (95% CI) p value
Group CVB1/5a CVB2/3/4/6b Controls (n = 181) Cases (n = 91)
1 – + 37.6 14.3 Ref.
2 – – 14.4 16.5 3.5 (1.3, 9.7) 0.015
3 + – 6.6 22.0 10.5 (3.7, 29.8) <0.001
4 + + 41.4 47.3 3.7 (1.5, 7.2) 0.002
Children were grouped based on the history of CVB infections into four groups at any time prior to islet
autoimmunity
The group with CVB infections other than CVB1/5 was used as the reference group
The OR and CI are shown with p values
a Refers to infection by any combinations of the following viruses: CVB1 or CVB5
bRefers to infections by any combinations of the following viruses: CVB2, 3, 4 or 6
Ref, Reference group
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The causative agents could not be identified since laboratory
testing was not carried out. However, it is known that these
symptoms are commonly caused by enterovirus infections.
CVB shares an important biological feature, which may
explain their tropism to beta cells; they are the only EVs that
use the Coxsackie and adenovirus receptor (CAR) to enter the
cell. CAR is expressed more strongly on the surface of beta
cells than other pancreatic cells [14] being selectively used by
CVBs to gain entry into the beta cells hence implying that they
may be responsible for the initiation of the process leading to
type 1 diabetes. This also indicates that all CVB types might
potentially cause beta cell damage. This feature could then be
modulated by other viral characteristics and/or beta cell sen-
sitivity to these viruses. In vitro studies have suggested that
EVs infect mainly beta cells in cultured human islets [15, 16],
and that CAR expression is upregulated in islets of individuals
with type 1 diabetes compared with controls [17]. In fact,
in vivo tropism of CVB to human pancreatic islets has also
been documented in post mortem examination of children
with a fatal CVB infection [18, 19]. Enterovirus capsid pro-
teins have been detected in beta cells from individuals with
type 1 diabetes as well, while other islet cells have been most-
ly virus negative [20–22]. A large proportion of individuals
affected by type 1 diabetes were reported to carry enterovirus
in a small number of pancreatic beta cells, supporting the
hypothesis of a chronic/persistent viral infection being present
in these individuals [14]. A chronic/persistent enterovirus in-
fection(s), with a slower rate of virus propagation, has already
been demonstrated in cell culture and mice models [23–25]
and it has been shown that a deletion at the 5′UTR end of the
viral genome could contribute to virus persistence in selected
human tissues [26, 27]. The presence of the 5′ end deletion
was also reported from a fatal case of fulminant enterovirus
myocarditis in Japan [28]. Therefore, we postulate that such a
persistent/chronic infection of the beta cells might be one of
the mechanisms initiating the autoimmune process.
The underlying mechanisms by which certain CVBs could
contribute to the autoimmune response against insulin but not
GAD are yet to be identified. One possible explanation,
though, would be the tropism of CVBs to beta cells where a
direct infection could induce autoimmunity against the most
abundant and exclusively expressed protein in these cells,
namely insulin. CVB infection could potentially induce
post-translational modifications of the insulin molecule ren-
dering it highly immunogenic. Interestingly, a recent publica-
tion showed that an incomplete response to CVB is associated
with insulin autoimmunity but not with GAD autoimmunity in
young children [29]. Collectively, these studies suggest that
further work is required to address the possible role of EVs in
type 1 diabetes particularly focusing on the IAA phenotype of
the disease.
One important aspect of our study is to report the existence
of a possible interaction between different CVB types: CVB1-
associated risk of islet autoimmunity was the highest in chil-
dren who experienced mainly CVB1 infections (or CVB1/5)
alone or prior to the other CVB infections. This indicates that
additional infections by other CVBs may attenuate the risk
association of CVB1 with islet autoimmunity. One possible
explanation to this phenomenon could be immunological
cross-protection between different CVB types, when earlier
CVB infections could provide partial protection against sub-
sequent CVB1 infection. In fact, an earlier study in mice has
demonstrated that infection by CVB3 can attenuate later in-
fection by CVB1 [30] supporting this hypothesis. T cell cross-
reactivity can be another possible mechanism explaining a
cross-protection process [31–35]. An alternative to the cross-
protection hypothesis could be the presence of an immunoreg-
ulatory effect in which autoimmune responses could be down-
regulated by earlier infections as reported before [36]. In this
case, CVB1 could possibly lack such an immunoregulatory
property due to different intrinsic properties of various CVB
group viruses in vivo. It is also possible that their potential
Table 4 Effect of the order of
CVB1/5 and CVB2/3/4/6 infec-
tions on the risk of insulin-driven
islet autoimmunity (IAA first
group)
Group Order of CVB infections Infection % OR (95% CI) p value
Controls
(n = 181)
Cases
(n = 91)
1 CVB2/3/4/6 alone or before CVB1/5a 52.5 25.3 Ref.
2 No infection 14.4 16.5 2.5 (1.0, 6.2) 0.044
3 CVB1/5 alone or before CVB2/3/4/6b 12.7 30.8 5.3 (2.4, 11.7) <0.001
4 CVB1/5 and CVB2/3/4/6 simultaneouslyc 20.4 27.5 2.6 (1.3, 5.2) 0.007
The group who had a combination of CVB2/3/4/6 infections without or before CVB1/5 was considered as the
reference group
aAny combination of infections by CVB2, 3, 4, or 6 without or prior to CVB1 or CVB5 infections
b Infected only with combinations of CVB1 and CVB5
cAny combination of at least one CVB1 or CVB5 infections at the same time as other CVBs
Ref, Reference group
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diabetogenic effect could overcome their immunoregulatory
effect.
The present observation that different CVB types can
show contrasting associations with type 1 diabetes and
possibly interact with each other, demonstrates the impor-
tance of the type of assays that are used to discriminate
between the type of the enterovirus infections involved,
i.e. virus neutralising assays which are highly specific for
the serotype used in the assay. In fact, when all CVBs
were analysed as a group, they showed no association
with insulin-driven autoimmunity even though CVB1
was strongly associated with the appearance of IAA, thus
demonstrating the importance of neutralising antibody as-
sessments. In addition, the results demonstrate the value
of prospective studies, which allows a time-ordered analy-
sis to be conducted (e.g. IAA or GADA being the first
appearing autoantibody and chronological order of differ-
ent CVB infections). Therefore, the large population size
and the prospective birth cohort design have clearly pro-
vided an important advantage, giving us an excellent op-
portunity to identify the association of CVB infections
with type 1 diabetes.
It is also important to consider the limitations of the current
study when interpreting the results. The study samples are
representative of the Finnish population; therefore, it would
be important to perform similar studies in other populations
where the epidemiology of CVBs might be different. Previous
studies have suggested that CVBs other than CVB1 (CVB4 in
particular) could be diabetogenic [20, 37]. Hence, it is also
important to keep in mind that the diabetogenic effect might
not be the characteristic of a single virus serotype. In other
words, other enterovirus types may also be associated with
type 1 diabetes, depending on the circulation and accumula-
tion of diabetogenic strains in different populations. In the
current study CVB5 association with the risk of islet autoim-
munity or type 1 diabetes was not statistically significant on its
own but in combination with CVB1 there was some associa-
tion. The lack of statistical significance for CVB5 could be
due to its substantially lower frequency compared with CVB1.
It is noteworthy that circulating strains of a single enterovirus
serotype may also widely differ for their non-structural pro-
teins, which may further affect the diabetogenicity of the viral
strains [38]. Therefore, it would be important to identify re-
combination events in circulating EVs in different popula-
tions. In line with this, we have previously shown that the
CVB1 strains have different properties encountering innate
immunity [39] and causing cell death in human islet cell cul-
tures [40], which further emphasises the possible role of strain
variations. Population dynamics of enterovirus infections and
levels of maternal enterovirus antibodies, which protect the
offspring against enteroviral infections, may also matter. For
example, the prevalence of enterovirus infections and levels of
maternal enterovirus antibodies are considerably lower in
Finland than in most other countries. It has been proposed that
this makes Finnish children particularly susceptible to the di-
abetogenic effect of these viruses [41]. In fact, in the present
study, 47.3–83.4% of the children lacked maternal CVB anti-
bodies in cord blood, depending on the CVB serotype in
question (data not shown).
Another limitation of the present study is that the identifi-
cation of CVB types was based solely on neutralising anti-
body analyses. Therefore, further studies identifying enterovi-
rus serotypes by direct sequencing from diabetic and predia-
betic children should be conducted. However, such studies
can easily be compromised by difficulties in identifying the
individual enterovirus serotypes in sufficient numbers, leading
to limited statistical power to address this question. For exam-
ple, we have previously observed an excess of enterovirus
RNA by RT-PCR in serial stool and blood samples collected
prior to autoantibody seroconversion from prospectively
followed children in the DIPP study [42, 43]. However, the
identification of the serotype of these enteroviruses by se-
quencing the viral genome was successful only in a portion
of samples where too few CVB viruses were identified to
enable us to analyse their association with the initiation of islet
autoimmunity. We also have to appreciate the general limita-
tions of the case−control study design including the risk of
selection bias. However, this study had a nested case−control
design that minimises selection and recall bias compared with
a conventional case−control study [44]. Nonetheless, it is
difficult to completely exclude a possible contribution of
unknown confounding factors to the observed association
between CVBs and islet autoimmunity. However, this was
minimised using strict matching criteria for the selection of
control children at an individual level.
In conclusion, the present study suggests that CVB infec-
tions could contribute to the development of type 1 diabetes
via a specific pathway characterised by IAA as the first
appearing islet autoantibody. An early infection by CVB1 or
possibly by some other CVBs such as CVB5, might lead to
the induction of an autoimmune response against insulin.
However, the underlying mechanism(s) remain to be identi-
fied and further studies are needed to fully characterise this
phenomenon. Large prospective studies conducted in different
populations are also crucial tools to achieve this goal.
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